As wages and benefits shrink, state workers are retiring in droves. On top of all the layoffs, these retirements amount to a huge brain drain of government employees, and the problem is likely to get worse given the yawning bud…
Let’s take the politics out of the debate over public sector unions and their benefits, and look strictly at the figures. When you strip away the rhetoric, you can chart two macroeconomic trends and two patterns of fiscally fo…
Generic drugs are expected to enjoy a banner year in 2011, prompting some investment pros to reformulate their portfolios to get a jump on the transition. For Goldman Sachs, that means betting on several wholesale distributors …
In an update Tuesday, Pfizer said it is discontinuing 15 of the projects in its development pipeline. The news comes a month after the world’s largest pharmaceutical company announced large research and development cuts were on…
The company has landed a lucrative flu-vaccine contract with the U.S. government. It’s worth $97 million over the first three years, and it can be extended for an additional two years, for a total contract value of $179.1 milli…